

BREAKTHROUGH PEPTIDE THERAPEUTICS

# Melbourne & Sydney shareholder briefings

**Perth, Australia, 27 November 2015:** Phylogica Limited (ASX: PYC) is hosting two shareholder/investor briefings on 1 & 2 December 2015 in Melbourne and Sydney.

CEO, Dr Richard Hopkins will present the latest Phylogica news, update on the company's platform, recent exciting progress on the in-house oncology programs and an overall update on the new drug development strategy.

Dates and times:

### Melbourne

Shareholder/investor Twilight Briefing 4:30pm - 1 December The Auditorium Level 12, 15 William Street Melbourne

## Sydney

Shareholder/investor Lunch Briefing 12:30pm - 2 December The Occidental Hotel 43 York Street Sydney

All shareholders and investors wishing to attend must RSVP at <a href="mailto:info@monsoon.com.au">info@monsoon.com.au</a> or (03) 9620 3333.

## For further information, please contact:

Dr Richard Hopkins Tel: +61 8 9489 7855

Email: richardh@phylogica.com

Rudi Michelson Monsoon Communications Tel: +61 3 9620 3333

Email: rudim@monsoon.com.au

#### About Phylogica

Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics from the most structurally diverse libraries available. The Company listed on the ASX in 2005 as a spin out from the Telethon Kids Institute (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). The Company's drug discovery platform is based on its proprietary Phylomer® libraries containing over 400 billion unique natural peptides, which have been optimised by evolutionary selection to adopt stable drug-like structures. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer® libraries and proprietary screening technologies in exchange for licence fees, milestones and royalties. Partners from discovery alliances within the last 5 years include Roche, MedImmune, Pfizer, Janssen, Cubist Pharmaceuticals and Genentech.